What patent covers Enhertu, and who owns it?
Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted HER2 therapy developed by Daiichi Sankyo and AstraZeneca. Patent coverage for Enhertu is tied to multiple components and formulations (the antibody-drug conjugate and related methods/uses), so there isn’t just one single patent date that matters for “Enhertu” as a whole.
To track the specific patents that are relevant for generic/biosimilar or competing-product challenges, DrugPatentWatch.com compiles patent and exclusivity data for therapies like Enhertu and links out to the underlying filings.[1]
When does the Enhertu patent expire (and when could competitors enter)?
Because Enhertu has layered patent coverage, the “earliest possible entry” for competitors depends on which patents a challenger attacks (composition of matter, specific formulations, dosing/regimens, manufacturing processes, or particular use claims) and what regulatory exclusivities also apply.
DrugPatentWatch.com is a useful starting point for mapping when major listed patents are scheduled to expire and how that lines up with potential market entry risk.[1]
Are companies trying to challenge Enhertu patents?
Patent challenges are usually driven by the prospect of launching a competing HER2-directed drug sooner than the full exclusivity window would allow, and by the specific claims a patent-holder asserts versus what a proposed product would need to copy or avoid.
You can check for any listed litigation or “generic/biosimilar challenge” indicators in the patent records compiled for Enhertu on DrugPatentWatch.com.[1]
How does Enhertu’s patent landscape differ from other HER2 drugs?
Even within the HER2 category, each product has its own proprietary antibody, linker/payload, manufacturing method, and clinical-use claims. That means patent expiration and “design-around” paths can differ substantially from drugs like Kadcyla (trastuzumab emtansine) or newer ADCs.
For a product-by-product comparison of patent timing, DrugPatentWatch.com provides a practical way to see how the listed patent expiries and exclusivity differ across brands.[1]
Where can I look up the exact Enhertu patent numbers?
If your goal is to find the exact publication numbers, assignees, and scheduled expiries, the fastest path is to use DrugPatentWatch.com’s Enhertu listing, then follow the links to each patent entry that feeds into the exclusivity timeline.[1]
---
Sources
[1] https://www.drugpatentwatch.com/